GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Debt-to-Asset

BioStem Technologies (BioStem Technologies) Debt-to-Asset : 1.04 (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Debt-to-Asset?

BioStem Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.61 Mil. BioStem Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.41 Mil. BioStem Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $5.81 Mil. BioStem Technologies's debt to asset for the quarter that ended in Sep. 2023 was 1.04.


BioStem Technologies Debt-to-Asset Historical Data

The historical data trend for BioStem Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Debt-to-Asset Chart

BioStem Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 1.62 2.11 1.81 1.47

BioStem Technologies Quarterly Data
Sep15 Dec15 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.47 1.62 1.04

Competitive Comparison of BioStem Technologies's Debt-to-Asset

For the Biotechnology subindustry, BioStem Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Debt-to-Asset falls into.



BioStem Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioStem Technologies's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

BioStem Technologies's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioStem Technologies  (OTCPK:BSEM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


BioStem Technologies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioStem Technologies (BioStem Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.